131 filings
6-K
IMTX
Immatics N.V
21 Mar 24
Current report (foreign)
7:48am
20-F
2023 FY
IMTX
Immatics N.V
Annual report (foreign)
21 Mar 24
7:23am
SC 13G/A
IMTX
Immatics N.V
14 Feb 24
Immatics / BAKER BROS. ADVISORS ownership change
4:21pm
SC 13G/A
IMTX
Immatics N.V
8 Feb 24
Immatics / WELLINGTON MANAGEMENT ownership change
10:05am
SC 13G/A
Athos KG
7 Feb 24
Immatics / ATHOS KG ownership change
5:10pm
SC 13G/A
lj2itx
7 Feb 24
Immatics / ATHOS KG ownership change
5:02pm
6-K
orf frry2
22 Jan 24
Immatics Announces Proposed Public Offering
12:52pm
424B5
xepz8paqc
19 Jan 24
Prospectus supplement for primary offering
8:58am
424B5
kablobm
17 Jan 24
Prospectus supplement for primary offering
4:11pm
6-K
qqnc9
14 Nov 23
Current report (foreign)
12:00am
6-K
5b2tkf9c epm6w3m7uvr
8 Nov 23
Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial
7:30am
6-K
2e5tz
24 Oct 23
Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy
7:10am
EFFECT
wpmhq8t
14 Sep 23
Notice of effectiveness
12:15am
424B3
bpyqutfmbc
13 Sep 23
Prospectus supplement
5:03pm
6-K
xns9rghuf6ic90cd2
11 Sep 23
Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics
6:33am
CORRESP
myp2m4aj9ws
11 Sep 23
Correspondence with SEC
12:00am
UPLOAD
rci47 wp9dv6jh21q
29 Aug 23
Letter from SEC
12:00am
F-3
8gher7fs0b25o eru81
25 Aug 23
Shelf registration (foreign)
4:11pm
6-K
ygz0spul1xe
17 Aug 23
Current report (foreign)
7:05am
SC 13G
nmbdjwhay2xug
16 Aug 23
Immatics / ATHOS KG ownership change
4:15pm